Both GLP-1 agonists and BPC-157 are short chains of amino acids
The BPC-157 Regulatory Timeline Why the April change was often misunderstood When FDA removed BPC-157 from Category 2 in April, some online posts described the change as permission to compound again
IGF-1 LR3 carries an arginine substitution at position 3 and an N-terminal 13-amino-acid extension that reduces IGFBP affinity by roughly 1,000-fold, extending its active window to 20-30 hours
Perfect B offers meaningful savings for patients who commit to two or three cycles upfront
Our GHK-Cu is synthesized in the USA in a cGMP (Current Good Manufacturing Practice) compliant facility, adhering to stringent manufacturing protocols
In Australia, healthcare providers are increasingly considering the adoption of needleless options, recognising their potential to enhance patient care